A Phase 1 interventional study of Rosuvastatin and Furosemide in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 24 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Merck Sharp & Dohme LLC · Phase 1, Interventional, and Basic science
Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF.
The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Participants receive rosuvastatin and MK-2828 orally.
Drug: Rosuvastatin · Drug: MK-2828
Participants receive furosemide and MK-2828 orally.
Drug: Furosemide · Drug: MK-2828
Oral administration
Oral administration
Oral administration
Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Rosuvastatin
Blood samples will be collected to determine the AUC0-inf of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Furosemide
Blood samples will be collected to determine the AUC0-inf of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 1 month
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 2 weeks
Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Rosuvastatin
Blood samples will be collected to determine the AUC0-last of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Furosemide
Blood samples will be collected to determine the AUC0-last of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Rosuvastatin
Blood samples will be collected to determine the AUC0-24 of rosuvastatin.
Time frame: At designated time points (up to approximately 24 hours)
Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Furosemide
Blood samples will be collected to determine the AUC0-24 of furosemide.
Time frame: At designated time points (up to approximately 24 hours)
Maximum Plasma Concentration (Cmax) of Rosuvastatin
Blood samples will be collected to determine the Cmax of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Maximum Plasma Concentration (Cmax) of Furosemide
Blood samples will be collected to determine the Cmax of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Time of the Maximum Plasma Concentration (Tmax) of Rosuvastatin
Blood samples will be collected to determine the Tmax of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Time of the Maximum Plasma Concentration (Tmax) of Furosemide
Blood samples will be collected to determine the Tmax of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Terminal Half-life (t1/2) of Rosuvastatin
Blood samples will be collected to determine the t1/2 of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Terminal Half-life (t1/2) of Furosemide
Blood samples will be collected to determine the t1/2 of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Apparent Total Plasma Clearance (CL/F) of Rosuvastatin
Blood samples will be collected to determine the CL/F of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Apparent Total Plasma Clearance (CL/F) of Furosemide
Blood samples will be collected to determine the CL/F of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Rosuvastatin
Blood samples will be collected to determine the Vz/F of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Furosemide
Blood samples will be collected to determine the Vz/F of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC